Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem.

Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME, Weinstein MP, Sexton DJ.

Clin Microbiol Rev. 2019 Oct 30;33(1). pii: e00009-19. doi: 10.1128/CMR.00009-19. Print 2019 Dec 18. Review.

PMID:
31666280
2.

Complete Genome Sequence of Clostridioides difficile Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing.

Spinler JK, Gonzales-Luna AJ, Raza S, Runge JK, Luna RA, Savidge TC, Garey KW.

Microbiol Resour Announc. 2019 Oct 17;8(42). pii: e00935-19. doi: 10.1128/MRA.00935-19.

3.

Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms.

Rashid T, Haghighi F, Hasan I, Bassères E, Alam MJ, Sharma SV, Lai D, DuPont HL, Garey KW.

Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01031-19. doi: 10.1128/AAC.01031-19. [Epub ahead of print]

PMID:
31611365
4.

Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile infection.

Garey KW.

Clin Infect Dis. 2019 Sep 27. pii: ciz970. doi: 10.1093/cid/ciz970. [Epub ahead of print] No abstract available.

PMID:
31560048
5.

Combating resistance while maintaining innovation: the future of antimicrobial stewardship.

Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenberg DE, Nguyen MH, Roblin D, Tillotson GS, Wilcox MH.

Future Microbiol. 2019 Sep 17. doi: 10.2217/fmb-2019-0227. [Epub ahead of print]

6.

Toxin A-predominant Pathogenic C. difficile: A Novel Clinical Phenotype.

Lin Q, Pollock NR, Banz A, Lantz A, Xu H, Gu L, Gerding DN, Garey KW, Gonzales-Luna AJ, Zhao M, Song L, Duffy DC, Kelly CP, Chen X.

Clin Infect Dis. 2019 Aug 11. pii: ciz727. doi: 10.1093/cid/ciz727. [Epub ahead of print]

PMID:
31400280
7.

A systematic approach to optimize electronic health record medication alerts in a health system.

Bhakta SB, Colavecchia AC, Haines L, Varkey D, Garey KW.

Am J Health Syst Pharm. 2019 Apr 8;76(8):530-536. doi: 10.1093/ajhp/zxz012.

PMID:
31361861
8.

Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh.

Sofjan AK, Islam MA, Halder K, Kabir ND, Saleh AA, Miranda J, Lancaster C, Begum K, Alam MJ, Garey KW.

Anaerobe. 2019 Jul 26:102081. doi: 10.1016/j.anaerobe.2019.102081. [Epub ahead of print]

PMID:
31356958
9.

Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil.

Rainha K, Fernandes Ferreira R, Trindade CNR, Carneiro LG, Penna B, Endres BT, Begum K, Alam MJ, Garey KW, Domingues Regina Maria CP, Ferreira EO.

Anaerobe. 2019 Aug;58:22-29. doi: 10.1016/j.anaerobe.2019.06.007. Epub 2019 Jun 17.

PMID:
31220606
10.

Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways.

Engevik MA, Luk B, Chang-Graham AL, Hall A, Herrmann B, Ruan W, Endres BT, Shi Z, Garey KW, Hyser JM, Versalovic J.

MBio. 2019 Jun 18;10(3). pii: e01087-19. doi: 10.1128/mBio.01087-19.

11.

Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals.

Alam MJ, McPherson J, Miranda J, Thrall A, Ngo V, Kessinger R, Begum K, Marin M, Garey KW.

Anaerobe. 2019 Oct;59:107-111. doi: 10.1016/j.anaerobe.2019.06.005. Epub 2019 Jun 15.

PMID:
31207298
12.

Economic health care costs of blood culture contamination: A systematic review.

Dempsey C, Skoglund E, Muldrew KL, Garey KW.

Am J Infect Control. 2019 Aug;47(8):963-967. doi: 10.1016/j.ajic.2018.12.020. Epub 2019 Feb 20. Review.

PMID:
30795840
13.

Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh.

Islam MA, Kabir ND, Moniruzzaman M, Begum K, Ahmed D, Faruque ASG, Garey KW, Alam MJ.

Anaerobe. 2019 Apr;56:88-90. doi: 10.1016/j.anaerobe.2019.02.010. Epub 2019 Feb 19.

PMID:
30794875
14.

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains.

Endres BT, Begum K, Sun H, Walk ST, Memariani A, Lancaster C, Gonzales-Luna AJ, Dotson KM, Bassères E, Offiong C, Tupy S, Kuper K, Septimus E, Arafat R, Alam MJ, Zhao Z, Hurdle JG, Savidge TC, Garey KW.

Open Forum Infect Dis. 2019 Feb 9;6(2):ofz013. doi: 10.1093/ofid/ofz013. eCollection 2019 Feb.

15.

Ridinilazole for the treatment of Clostridioides difficile infection.

Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW.

Expert Opin Investig Drugs. 2019 Apr;28(4):303-310. doi: 10.1080/13543784.2019.1582640. Epub 2019 Feb 26. Review.

PMID:
30767587
16.

Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection.

Yee KL, Kleijn HJ, Kerbusch T, Matthews RP, Dorr MB, Garey KW, Wrishko RE.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01971-18. doi: 10.1128/AAC.01971-18. Print 2019 Feb.

17.

Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis.

Skoglund E, Dempsey CJ, Chen H, Garey KW.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01015-18. doi: 10.1128/JCM.01015-18. Print 2019 Jan.

18.

Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing.

Endres BT, Dotson KM, Poblete K, McPherson J, Lancaster C, Bassères E, Memariani A, Arnold S, Tupy S, Carlsen C, Morehead B, Anyatonwu S, Cook C, Begum K, Alam MJ, Garey KW.

Infect Control Hosp Epidemiol. 2018 Nov;39(11):1322-1329. doi: 10.1017/ice.2018.230. Epub 2018 Sep 26.

19.

Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge.

Reveles KR, Dotson KM, Gonzales-Luna A, Surati D, Endres BT, Alam MJ, Garey KW.

Clin Infect Dis. 2019 May 17;68(11):1887-1893. doi: 10.1093/cid/ciy782.

20.

In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals.

Beyda ND, Amadio J, Rodriguez JR, Malinowski K, Garey KW, Wanger A, Ostrosky-Zeichner L.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00471-18. doi: 10.1128/JCM.00471-18. Print 2018 Aug.

21.

Reply to Fabre et al.

McDonald LC, Johnson S, Bakken JS, Garey KW, Kelly C, Gerding DN.

Clin Infect Dis. 2018 Nov 28;67(12):1958-1959. doi: 10.1093/cid/ciy475. No abstract available.

PMID:
29860268
22.

Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA.

Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, Yau R, Restrepo A, Garey KW.

J Glob Antimicrob Resist. 2018 Dec;15:41-47. doi: 10.1016/j.jgar.2018.05.015. Epub 2018 May 26.

PMID:
29842975
23.

Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy.

Bhakta SB, Colavecchia AC, Coffey W, Curlee DR, Garey KW.

Am J Health Syst Pharm. 2018 Jun 1;75(11 Supplement 2):S51-S57. doi: 10.2146/ajhp170461.

PMID:
29802179
24.

Outcomes associated with Clostridium difficile infection in patients with chronic liver disease.

Dotson KM, Aitken SL, Sofjan AK, Shah DN, Aparasu RR, Garey KW.

Epidemiol Infect. 2018 Jul;146(9):1101-1105. doi: 10.1017/S0950268818001036. Epub 2018 May 9.

25.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.

PMID:
29562266
26.

Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship.

Sofjan AK, Casey BO, Xu BA, Amadio J, Restrepo A, Alam MJ, Garey KW.

Ann Pharmacother. 2018 Aug;52(8):754-762. doi: 10.1177/1060028018765486. Epub 2018 Mar 20.

PMID:
29557208
27.

Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy.

Sofjan AK, Mitchell A, Shah DN, Nguyen T, Sim M, Trojcak A, Beyda ND, Garey KW.

J Glob Antimicrob Resist. 2018 Sep;14:58-64. doi: 10.1016/j.jgar.2018.02.013. Epub 2018 Feb 24.

28.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.

29.

Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection.

Davis ML, Sparrow HG, Ikwuagwu JO, Musick WL, Garey KW, Perez KK.

Clin Microbiol Infect. 2018 Nov;24(11):1190-1194. doi: 10.1016/j.cmi.2018.02.013. Epub 2018 Feb 16.

30.

Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.

Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR 3rd, Garey KW, Reboli A, Greenberg RN, Apewokin S, Lyon GM 3rd, Ostrosky-Zeichner L, Wu AHB, Tobin E, Nguyen MH, Caliendo AM.

Clin Infect Dis. 2018 May 17;66(11):1678-1686. doi: 10.1093/cid/cix1095.

PMID:
29438475
31.

Investigating inpatient medication administration using the theory of planned behavior.

Rogers JW, Fleming M, Tipton J, Ward A, Garey KW, Pitman EP.

Am J Health Syst Pharm. 2017 Dec 15;74(24):2065-2070. doi: 10.2146/ajhp160502.

PMID:
29222364
32.

Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms.

Addo Smith JN, Yau R, Russo HP, Putney K, Restrepo A, Garey KW, Sofjan AK.

J Clin Gastroenterol. 2018 Aug;52(7):648-654. doi: 10.1097/MCG.0000000000000964.

PMID:
29176351
33.

Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients.

Rashid T, Poblete K, Amadio J, Hasan I, Begum K, Alam MJ, Garey KW.

J Hosp Infect. 2018 Jan;98(1):96-101. doi: 10.1016/j.jhin.2017.10.011. Epub 2017 Oct 21.

PMID:
29066141
34.

Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S, Tessier ME, von Rosenvinge EC, Kelly CP, Pasetti MF, Feng H.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00037-17. doi: 10.1128/CVI.00037-17. Print 2017 Aug.

35.

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.

Endres B, Bassères E, Rashid T, Chang L, Alam MJ, Garey KW.

J Vis Exp. 2017 May 25;(123). doi: 10.3791/55383.

36.

Community Environmental Contamination of Toxigenic Clostridium difficile.

Alam MJ, Walk ST, Endres BT, Basseres E, Khaleduzzaman M, Amadio J, Musick WL, Christensen JL, Kuo J, Atmar RL, Garey KW.

Open Forum Infect Dis. 2017 Feb 10;4(1):ofx018. doi: 10.1093/ofid/ofx018. eCollection 2017 Winter.

37.

Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection.

Shea KM, Hobbs ALV, Jaso TC, Bissett JD, Cruz CM, Douglass ET, Garey KW.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00125-17. doi: 10.1128/AAC.00125-17. Print 2017 Jun.

38.

Cadazolid for the treatment of Clostridium difficile.

Endres BT, Bassères E, Alam MJ, Garey KW.

Expert Opin Investig Drugs. 2017 Apr;26(4):509-514. doi: 10.1080/13543784.2017.1304538. Review.

PMID:
28286992
39.

Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population.

Cox SR, Liebl MG, McComb MN, Chau JQ, Wilson AA, Achi M, Garey KW, Wallace D.

Res Social Adm Pharm. 2017 Jul - Aug;13(4):754-758. doi: 10.1016/j.sapharm.2016.09.003. Epub 2016 Oct 14.

PMID:
28277275
40.

Novel antibiotics in development to treat Clostridium difficile infection.

Bassères E, Endres BT, Dotson KM, Alam MJ, Garey KW.

Curr Opin Gastroenterol. 2017 Jan;33(1):1-7. doi: 10.1097/MOG.0000000000000332. Review.

PMID:
28134686
41.

Mechanisms for floor surfaces or environmental ground contamination to cause human infection: a systematic review.

Rashid T, Vonville H, Hasan I, Garey KW.

Epidemiol Infect. 2017 Jan;145(2):347-357. Epub 2016 Oct 26. Review.

PMID:
27780492
42.

Shoe soles as a potential vector for pathogen transmission: a systematic review.

Rashid T, VonVille HM, Hasan I, Garey KW.

J Appl Microbiol. 2016 Nov;121(5):1223-1231. doi: 10.1111/jam.13250. Epub 2016 Sep 19. Review.

43.

A multi-center study of fidaxomicin use for Clostridium difficile infection.

Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW.

Springerplus. 2016 Aug 2;5(1):1224. doi: 10.1186/s40064-016-2825-x. eCollection 2016.

44.

Ridinilazole: a novel therapy for Clostridium difficile infection.

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH.

Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Review.

45.

Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.

Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW.

J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.

PMID:
27209056
46.

Benchmarking and medication error rates.

Gorbach C, Blanton L, Lukawski B, Varkey AC, Pitman P, Garey KW.

Am J Health Syst Pharm. 2016 Jun 1;73(11):746. doi: 10.2146/ajhp150961. No abstract available.

PMID:
27208057
47.

A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.

Endres BT, Bassères E, Memariani A, Chang L, Alam MJ, Vickers RJ, Kakadiaris IA, Garey KW.

Anaerobe. 2016 Aug;40:10-4. doi: 10.1016/j.anaerobe.2016.04.013. Epub 2016 Apr 21.

PMID:
27108094
48.

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.

Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP.

Ann Clin Microbiol Antimicrob. 2016 Apr 12;15:22. doi: 10.1186/s12941-016-0140-6.

49.

Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.

Endres BT, Bassères E, Khaleduzzaman M, Alam MJ, Chesnel L, Garey KW.

Antimicrob Agents Chemother. 2016 May 23;60(6):3519-23. doi: 10.1128/AAC.00211-16. Print 2016 Jun.

50.

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.

Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW.

J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18.

Supplemental Content

Loading ...
Support Center